Luciana Molinero

13.8k total citations · 6 hit papers
102 papers, 9.2k citations indexed

About

Luciana Molinero is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luciana Molinero has authored 102 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 37 papers in Immunology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luciana Molinero's work include Cancer Immunotherapy and Biomarkers (56 papers), Advanced Breast Cancer Therapies (21 papers) and Immune Cell Function and Interaction (20 papers). Luciana Molinero is often cited by papers focused on Cancer Immunotherapy and Biomarkers (56 papers), Advanced Breast Cancer Therapies (21 papers) and Immune Cell Function and Interaction (20 papers). Luciana Molinero collaborates with scholars based in United States, United Kingdom and France. Luciana Molinero's co-authors include Leisha A. Emens, Hiroji Iwata, Sylvia Adams, Carlos H. Barrios, Jane Yuet Ching Hui, Peter Schmid, Sherene Loi, Véronique Dièras, Eric P. Winer and Hope S. Rugo and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Luciana Molinero

100 papers receiving 9.1k citations

Hit Papers

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negati... 2018 2026 2020 2023 2018 2019 2020 2018 2021 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    2018 3.0k citations Peter Schmid, Sylvia Adams et al. profile →
  2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
    2019 846 citations Peter Schmid, Hope S. Rugo et al. The Lancet Oncology profile →
  3. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
    2020 718 citations Carlos H. Barrios, Shigehira Saji et al. profile →
  4. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
    2018 567 citations Leisha A. Emens, Cristina Cruz et al. profile →
  5. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
    2021 293 citations Leisha A. Emens, Sylvia Adams et al. Annals of Oncology profile →
  6. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
    2021 205 citations Leisha A. Emens, Luciana Molinero et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luciana Molinero United States 37 6.6k 3.4k 2.2k 2.1k 1.6k 102 9.2k
Peter Schmid United Kingdom 44 8.3k 1.3× 2.6k 0.8× 3.5k 1.6× 3.2k 1.5× 2.1k 1.3× 207 11.0k
Roberto Salgado Belgium 34 6.5k 1.0× 2.9k 0.9× 1.7k 0.8× 2.6k 1.2× 1.7k 1.1× 147 8.7k
Helen K. Angell United Kingdom 22 4.0k 0.6× 2.7k 0.8× 1.9k 0.9× 1.4k 0.7× 2.1k 1.3× 40 6.5k
E. Gabriela Chiorean United States 42 4.7k 0.7× 1.7k 0.5× 1.5k 0.7× 1.7k 0.8× 2.1k 1.3× 209 7.1k
Theodore F. Logan United States 37 4.5k 0.7× 2.1k 0.6× 3.2k 1.5× 1.5k 0.7× 3.3k 2.0× 120 8.0k
Junzo Hamanishi Japan 33 4.4k 0.7× 3.6k 1.0× 965 0.4× 873 0.4× 1.7k 1.0× 142 7.4k
Matteo S. Carlino Australia 51 9.6k 1.4× 3.7k 1.1× 2.0k 0.9× 1.5k 0.7× 4.7k 2.9× 303 12.5k
Yosuke Togashi Japan 39 4.2k 0.6× 2.0k 0.6× 2.3k 1.1× 866 0.4× 1.6k 1.0× 156 6.4k
Leena Gandhi United States 46 5.8k 0.9× 1.8k 0.5× 4.1k 1.9× 1.3k 0.6× 2.7k 1.7× 145 8.6k
Mark Ayers United States 33 5.2k 0.8× 1.6k 0.5× 1.9k 0.9× 2.7k 1.3× 2.5k 1.5× 56 7.8k

Countries citing papers authored by Luciana Molinero

Since Specialization
Citations

This map shows the geographic impact of Luciana Molinero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luciana Molinero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luciana Molinero more than expected).

Fields of papers citing papers by Luciana Molinero

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luciana Molinero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luciana Molinero. The network helps show where Luciana Molinero may publish in the future.

Co-authorship network of co-authors of Luciana Molinero

This figure shows the co-authorship network connecting the top 25 collaborators of Luciana Molinero. A scholar is included among the top collaborators of Luciana Molinero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luciana Molinero. Luciana Molinero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiao, Li, Jeffrey Eastham, Jennifer M. Giltnane, et al.. (2024). Automated tumor immunophenotyping predicts clinical benefit from anti‐PD‐L1 immunotherapy. The Journal of Pathology. 263(2). 190–202. 6 indexed citations
2.
McCormack, Mary, Yong‐Man Kim, Sharad Ghamande, et al.. (2024). A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04). International Journal of Gynecological Cancer. 34(8). 1140–1148. 16 indexed citations
3.
Kristeleit, Rebecca, Alexandra Léary, Ana Oaknin, et al.. (2024). PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. British Journal of Cancer. 131(5). 820–831. 12 indexed citations
4.
Harbeck, Nadia, Chaojun Duan, Kelly DuPree, et al.. (2023). 2232O Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031. Annals of Oncology. 34. S1149–S1150.
5.
Herbst, Roy S., Daniel Ruderman, James F. Conway, et al.. (2023). OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell Scoring on SP263-Stained Whole Imaging Slides from IMpower110. Journal of Thoracic Oncology. 18(11). S79–S80. 2 indexed citations
6.
Sokol, Ethan S., Dexter X. Jin, Alexander D. Fine, et al.. (2022). PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers. JCO Precision Oncology. 6(6). e2100531–e2100531. 20 indexed citations
7.
Emens, Leisha A., Sylvia Adams, Carlos H. Barrios, et al.. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of Oncology. 32(8). 983–993. 293 indexed citations breakdown →
8.
Hamilton, Erika, Virginia Kaklamani, Carla I. Falkson, et al.. (2021). Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Clinical Breast Cancer. 21(6). 539–551. 28 indexed citations
9.
10.
Lowe, Christopher J., Shilpi Mahajan, Mike Reichelt, et al.. (2020). Enrichment of circulating tumor-derived extracellular vesicles from human plasma. Journal of Immunological Methods. 490. 112936–112936. 27 indexed citations
11.
Hamid, Omid, Luciana Molinero, Christopher R. Bolen, et al.. (2019). Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research. 25(20). 6061–6072. 58 indexed citations
12.
Schmid, Peter, Hope S. Rugo, Sylvia Adams, et al.. (2019). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 21(1). 44–59. 846 indexed citations breakdown →
13.
Wongchenko, Matthew, Grant A. McArthur, Brigitte Dréno, et al.. (2017). Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clinical Cancer Research. 23(17). 5238–5245. 28 indexed citations
14.
Schmid, Peter, Cristina Cruz, Fadi S. Braiteh, et al.. (2017). Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Research. 77(13_Supplement). 2986–2986. 92 indexed citations
15.
Bahleda, Rastislav, Fadi S. Braiteh, Ani Sarkis Balmanoukian, et al.. (2017). Long-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results. Annals of Oncology. 28. v373–v373. 21 indexed citations
16.
Lei, Yuk Man, Luqiu Chen, Ying Wang, et al.. (2016). The composition of the microbiota modulates allograft rejection. Journal of Clinical Investigation. 126(7). 2736–2744. 80 indexed citations
17.
Infante, J. R., Fadi Braiteh, Leisha A. Emens, et al.. (2016). Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC). Annals of Oncology. 27. vi300–vi300. 36 indexed citations
18.
Molinero, Luciana & Maria‐Luisa Alegre. (2011). TCR-CARMA1-NF-{kappa}B controls Th17 differentiation. The Journal of Immunology. 186. 1 indexed citations
19.
Manicassamy, Santhakumar, et al.. (2008). A Critical Role for Protein Kinase C-θ-Mediated T Cell Survival in Cardiac Allograft Rejection. The Journal of Immunology. 181(1). 513–520. 31 indexed citations
20.
Molinero, Luciana, et al.. (2003). Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis. Clinical Immunology. 106(1). 50–54. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Schmid Breakdown of academic impact, for papers by Roberto Salgado Breakdown of academic impact, for papers by Helen K. Angell Breakdown of academic impact, for papers by E. Gabriela Chiorean Breakdown of academic impact, for papers by Theodore F. Logan Breakdown of academic impact, for papers by Junzo Hamanishi Breakdown of academic impact, for papers by Matteo S. Carlino Breakdown of academic impact, for papers by Yosuke Togashi Breakdown of academic impact, for papers by Leena Gandhi Breakdown of academic impact, for papers by Mark Ayers
Rankless by CCL
2026